HEALTH-SOVEREIGNTY & MEDTECH DESK  ·  DISPATCH

The Biomedical Advanced Research and Development Authority (BARDA), the U.S. biodefense agency inside the Department of Health and Human Services, awarded True Diagnostics approximately US$11 million over 36 months through its Rapid Response Partnership Vehicle (RRPV) — an award, not yet a disbursed sum — to advance the company's VeriClear EbV MARV Rapid Antigen Test, a point-of-care diagnostic device for detecting Ebola and Marburg virus.

The instrument is the RRPV itself, a mechanism BARDA uses to move faster than its traditional milestone-based contracts by pre-qualifying partners and funding specific projects against an existing framework agreement rather than negotiating each award from scratch. That structure is built for exactly this kind of bet: a diagnostic device for two hemorrhagic-fever pathogens that have no reliable point-of-care test today, financed ahead of an outbreak rather than during one.

This is biosecurity reshoring at its smallest, most legible scale — a single device company, a defined pathogen pair, a three-year runway — rather than the large stockpile contracts or manufacturing-capacity awards that dominate the headline biodefense numbers. The device itself is the point: a rapid antigen test that can be deployed at the point of care sidesteps the laboratory turnaround time that has historically slowed outbreak response for both viruses.

What the award does not yet establish is whether the device clears regulatory review, reaches manufacturing scale, or gets stockpiled once developed — the gap between a 36-month development award and a fielded diagnostic device is exactly the gap that can widen or close unpredictably across a biodefense agency's own track record. The US$11 million buys time and a mandate to build; it does not yet buy a test in a field kit.

— Capital Statecraft Intelligence · Health-Sovereignty & MedTech Desk

Primary source(s): GlobeNewswire (True Diagnostics company press release), 20 October 2025